ACQUISITIONS, DIVESTITURE AND PRO FORMA RESULTS (Narrative) (Details) $ in Thousands |
|
|
|
|
|
|
|
1 Months Ended |
3 Months Ended |
6 Months Ended |
9 Months Ended |
10 Months Ended |
12 Months Ended |
|
Oct. 02, 2017
USD ($)
|
May 25, 2017
USD ($)
|
Apr. 04, 2017
USD ($)
|
Feb. 24, 2017
USD ($)
|
Dec. 15, 2015
USD ($)
|
Oct. 02, 2015
USD ($)
|
Jul. 17, 2015
USD ($)
acquisition
|
Oct. 31, 2017
USD ($)
|
Aug. 31, 2017
USD ($)
|
Apr. 30, 2017
USD ($)
|
Dec. 31, 2017
USD ($)
|
Sep. 30, 2017
USD ($)
|
Jun. 30, 2017
USD ($)
|
Mar. 31, 2017
USD ($)
|
Dec. 31, 2016
USD ($)
|
Sep. 30, 2016
USD ($)
|
Jun. 30, 2016
USD ($)
|
Mar. 31, 2016
USD ($)
|
Jun. 30, 2017
USD ($)
|
Dec. 31, 2017
USD ($)
|
Dec. 31, 2017
USD ($)
|
Dec. 31, 2017
USD ($)
|
Dec. 31, 2016
USD ($)
|
Dec. 31, 2015
USD ($)
|
Oct. 06, 2017
USD ($)
|
Business Acquisition [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Amount drawn from loan |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 1,307,000
|
$ 680,000
|
$ 545,000
|
|
Realized loss, included in other income, net |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 2,300
|
|
|
|
|
|
|
Deferred tax assets, other |
|
|
|
|
|
|
|
|
|
|
$ 3,077
|
|
|
|
$ 128
|
|
|
|
|
$ 3,077
|
$ 3,077
|
3,077
|
128
|
|
|
Payment for contingent consideration |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
4,661
|
0
|
0
|
|
Gain recognized, amount |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0
|
0
|
1,111
|
|
Number of businesses acquired | acquisition |
|
|
|
|
|
|
2
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash used in business acquisition, net of cash acquired |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,241,946
|
(225)
|
328,888
|
|
Contingent consideration, received from escrow |
|
|
|
|
|
|
|
|
|
$ 1,200
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Increase in fair value of contingent receivable |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,600
|
1,300
|
|
|
Net income (loss) |
|
|
|
|
|
|
|
|
|
|
44,355
|
$ 3,159
|
$ 10,835
|
$ 6,394
|
28,246
|
$ 20,144
|
$ 12,755
|
$ 13,419
|
|
|
|
64,743
|
74,564
|
(3,519)
|
|
Interest Expense, Intangible Asset Amortization, and External Expenses Related to Acquisition |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Business Acquisition [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 24,900
|
|
|
|
Product Concentration Risk | BioD Morselized Amniotic Membrane Based Products |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Business Acquisition [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Revenue from product, Percentage |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1.00%
|
|
|
|
Derma Sciences | Interest Expense, Intangible Asset Amortization, and External Expenses Related to Acquisition |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Business Acquisition [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 2,900
|
|
|
|
Codman Specialty Surgical |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Business Acquisition [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Aggregate purchase price received |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 46,400
|
Assets provided upon termination of transitional supply agreement liability |
|
|
|
|
|
|
|
|
|
|
1,300
|
|
|
|
|
|
|
|
|
1,300
|
1,300
|
1,300
|
|
|
|
Codman Specialty Surgical | Disposal Group, Held-for-sale, Not Discontinued Operations |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Business Acquisition [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gain on sale of business, included in other income, net |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2,600
|
|
|
|
Term loan A-1 | Secured Debt |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Business Acquisition [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Amount drawn from loan |
|
|
|
|
|
|
|
$ 700,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Codman |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Business Acquisition [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Consideration transferred |
$ 1,014,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Write off of construction in progress |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
6,300
|
|
|
|
Revenue since acquisition date |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
76,900
|
|
|
|
Net assets acquired |
|
|
|
|
|
|
|
|
|
|
1,014,091
|
|
|
|
|
|
|
|
|
1,014,091
|
1,014,091
|
1,014,091
|
|
|
|
Codman | Term loan A-1 | Secured Debt |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Business Acquisition [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Amount drawn from loan |
$ 700,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
TGX Medical |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Business Acquisition [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Consideration transferred |
|
|
$ 5,400
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Revenue since acquisition date |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
600
|
|
|
|
|
|
Business combination, cash acquired |
|
|
|
|
|
|
|
|
|
|
49
|
|
|
|
|
|
|
|
|
49
|
49
|
49
|
|
|
|
Net assets acquired |
|
|
|
|
|
|
|
|
|
|
5,367
|
|
|
|
|
|
|
|
|
5,367
|
5,367
|
5,367
|
|
|
|
Derma Sciences |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Business Acquisition [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Consideration transferred |
|
|
|
$ 210,800
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Revenue since acquisition date |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
84,600
|
|
|
|
|
Payment of closing expenses |
|
|
|
4,800
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Payment of stock plan settlement |
|
|
|
4,300
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Payments to acquire business |
|
|
|
$ 201,700
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Preliminary purchase price allocation adjustment |
|
|
|
|
|
|
|
|
|
|
|
|
1,700
|
|
|
|
|
|
|
|
|
|
|
|
|
Adjustment to purchase price and goodwill |
|
|
|
|
|
|
|
|
|
|
|
$ 300
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Deferred taxes |
|
|
|
|
|
|
|
|
|
|
14,524
|
|
|
|
|
|
|
|
|
14,524
|
14,524
|
14,524
|
|
|
|
Deferred tax assets, operating loss carryforwards |
|
|
|
|
|
|
|
|
|
|
39,700
|
|
|
|
|
|
|
|
|
39,700
|
39,700
|
39,700
|
|
|
|
Deferred tax assets, goodwill and intangible assets |
|
|
|
|
|
|
|
|
|
|
16,400
|
|
|
|
|
|
|
|
|
16,400
|
16,400
|
16,400
|
|
|
|
Deferred tax liabilities, intangible assets |
|
|
|
|
|
|
|
|
|
|
41,100
|
|
|
|
|
|
|
|
|
41,100
|
41,100
|
41,100
|
|
|
|
Deferred tax assets, other |
|
|
|
|
|
|
|
|
|
|
500
|
|
|
|
|
|
|
|
|
500
|
500
|
500
|
|
|
|
Adjustment, deferred tax assets |
|
|
|
|
|
|
|
|
|
|
3,300
|
|
1,500
|
|
|
|
|
|
$ 1,500
|
3,300
|
3,300
|
3,300
|
|
|
|
Business combination, cash acquired |
|
|
|
|
|
|
|
|
|
|
16,512
|
|
|
|
|
|
|
|
|
16,512
|
16,512
|
16,512
|
|
|
|
Net assets acquired |
|
|
|
|
|
|
|
|
|
|
210,478
|
|
|
|
|
|
|
|
|
210,478
|
210,478
|
210,478
|
|
|
|
Derma Sciences | BioD Earnout Payments |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Business Acquisition [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Revenue volatility |
|
|
|
13.50%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Discount rate |
|
|
|
3.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Contingent consideration arrangements, maximum payout |
|
|
|
$ 26,500
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Contingent consideration, liability |
|
|
|
$ 9,100
|
|
|
|
|
|
|
300
|
|
|
|
|
|
|
|
|
300
|
300
|
300
|
|
|
|
Payment for contingent consideration |
|
|
|
|
|
|
|
|
$ 4,800
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
4,000
|
|
|
|
Derma Sciences | Product Payment Contingent Consideration |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Business Acquisition [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Discount rate |
|
|
|
2.50%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Contingent consideration arrangements, maximum payout |
|
|
|
$ 29,700
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Contingent consideration, liability |
|
|
|
$ 26,800
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Product payment probability rate |
|
|
|
98.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Change in fair value of contingent consideration |
|
|
|
|
|
|
|
|
|
|
|
|
$ 900
|
|
|
|
|
|
|
|
|
|
|
|
|
Payment for contingent consideration liability |
|
$ 26,600
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Derma Sciences | Medihoney Earnout Payments |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Business Acquisition [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Revenue volatility |
|
|
|
27.50%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Discount rate |
|
|
|
4.50%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Contingent consideration arrangements, maximum payout |
|
|
|
$ 5,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Contingent consideration, liability |
|
|
|
$ 1,400
|
|
|
|
|
|
|
1,400
|
|
|
|
|
|
|
|
|
1,400
|
1,400
|
1,400
|
|
|
|
Tekmed |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Business Acquisition [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Consideration transferred |
|
|
|
|
$ 14,100
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net assets acquired |
|
|
|
|
|
|
|
|
|
|
14,103
|
|
|
|
|
|
|
|
|
14,103
|
14,103
|
14,103
|
|
|
|
Salto and Futura |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Business Acquisition [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Payments to acquire business |
|
|
|
|
|
$ 6,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net assets acquired |
|
|
|
|
|
|
|
|
|
|
7,111
|
|
|
|
|
|
|
|
|
7,111
|
7,111
|
7,111
|
|
|
|
Salto and Futura | Other Income |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Business Acquisition [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gain recognized, amount |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 1,100
|
|
TEI |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Business Acquisition [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Consideration transferred |
|
|
|
|
|
|
$ 312,200
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Adjustment to purchase price and goodwill |
|
|
|
|
|
|
$ 200
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(174)
|
|
|
Discount rate |
|
|
|
|
|
|
11.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash used in business acquisition, net of cash acquired |
|
|
|
|
|
|
$ 312,400
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Business combination, cash acquired |
|
|
|
|
|
|
1,200
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Contingent receivable |
|
|
|
|
|
|
400
|
|
|
|
$ 2,000
|
|
|
|
1,700
|
|
|
|
|
$ 2,000
|
$ 2,000
|
$ 2,000
|
1,700
|
|
|
Contingent consideration, asset, revenue threshold to realize asset |
|
|
|
|
|
|
6,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
TEI | Prepaid Expenses and Other Current Assets |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Business Acquisition [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Contingent receivable |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,200
|
|
|
|
|
|
|
|
1,200
|
|
|
TEI | Other assets |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Business Acquisition [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Contingent receivable |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 500
|
|
|
|
|
|
|
|
$ 500
|
|
|
TEI Biosciences Inc. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Business Acquisition [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Consideration transferred |
|
|
|
|
|
|
210,900
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Adjustment to purchase price and goodwill |
|
|
|
|
|
|
500
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
TEI Medical Inc. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Business Acquisition [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Consideration transferred |
|
|
|
|
|
|
101,300
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Adjustment to purchase price and goodwill |
|
|
|
|
|
|
$ 700
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|